Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547554 · ClinicalTrials.gov registry record · Phase 1
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
A Phase 1 study, sponsored by Qpex Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT06547554 is a Phase 1 study that has completed, run by Qpex Biopharma. The registered enrollment target is 60 participants.
The verdict
NCT06547554, a Phase 1 study, has completed, sponsored by Qpex Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
Interventions
- DRUG Cefiderocol
- DRUG Xeruborbactam
- DRUG Xeruborbactam/Cefiderocol
- DRUG Dextrose 5% in water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06547554
The ClinicalTrials.gov registry entry for NCT06547554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qpex Biopharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cefiderocol is the first listed.
NCT06547554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06547554 about?
NCT06547554 is a clinical study titled "A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants". A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
What is the current status of trial NCT06547554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-09-04. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT06547554?
The interventions under investigation include: Cefiderocol (DRUG), Xeruborbactam (DRUG), Xeruborbactam/Cefiderocol (DRUG), Dextrose 5% in water (DRUG).
Who is sponsoring clinical trial NCT06547554?
This trial is sponsored by Qpex Biopharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.